Joshua B. Cohen
CIK: 0001898644
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (21 total)
- Sep 10, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct29.5K shares at avg. $32.16$950K - Sep 10, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct919 shares at avg. $33.15$30K - Aug 18, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Award(A)Direct60K shares- - Mar 5, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Award(A)Direct248.9K shares- - Mar 2, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct29.3K shares at avg. $14.48$424K - Feb 2, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct15.5K shares at avg. $14.68$228K - Jan 16, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct2K shares at avg. $13.83$27K - Jan 16, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Exercise(M)Direct2.8K shares at avg. $7.57$21K - Jan 15, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct136.2K shares at avg. $13.59$1.9M - Jan 15, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Exercise(M)Direct197.2K shares at avg. $7.57$1.5M - Jan 6, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct7.7K shares at avg. $11.09$86K - Sep 30, 2025AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct200 shares at avg. $15.00$3K - Sep 30, 2025AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct29.7K shares at avg. $14.34$426K - Mar 31, 2025AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct21.5K shares at avg. $3.47$74K - Mar 6, 2025AMLX
Amylyx Pharmaceuticals, Inc.
Award(A)Direct180.1K shares- - Mar 3, 2025AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct4.6K shares at avg. $3.17$15K - Feb 3, 2025AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct11.9K shares at avg. $3.47$41K - Jan 6, 2025AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct7.5K shares at avg. $4.05$30K - Sep 30, 2024AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct18.6K shares at avg. $3.20$59K - Sep 23, 2024AMLX
Amylyx Pharmaceuticals, Inc.
Exercise(M)Direct1.9K shares at avg. $1.57$3K - Sep 12, 2024AMLX
Amylyx Pharmaceuticals, Inc.
Exercise(M)Direct34.4K shares at avg. $1.57$54K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 10, 2026 |  AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 29,545 | $32.16 | $950,040 | Direct |
| Sep 10, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 919 | $33.15 | $30,464 | Direct |
| Aug 18, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Award(A) | 60,039 | - | $0 | Direct |
| Mar 5, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Award(A) | 248,865 | - | $0 | Direct |
| Mar 2, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 29,282 | $14.48 | $424,120 | Direct |
| Feb 2, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 15,500 | $14.68 | $227,593 | Direct |
| Jan 16, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 1,974 | $13.83 | $27,299 | Direct |
| Jan 16, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Exercise(M) | 2,818 | $7.57 | $21,332 | Direct |
| Jan 15, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 136,193 | $13.59 | $1,850,795 | Direct |
| Jan 15, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Exercise(M) | 197,182 | $7.57 | $1,492,668 | Direct |
| Jan 6, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 7,715 | $11.09 | $85,596 | Direct |
| Sep 30, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 200 | $15.00 | $3,000 | Direct |
| Sep 30, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 29,733 | $14.34 | $426,469 | Direct |
| Mar 31, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 21,490 | $3.47 | $74,482 | Direct |
| Mar 6, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Award(A) | 180,118 | - | - | Direct |
| Mar 3, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 4,595 | $3.17 | $14,549 | Direct |
| Feb 3, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 11,851 | $3.47 | $41,108 | Direct |
| Jan 6, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 7,471 | $4.05 | $30,232 | Direct |
| Sep 30, 2024 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 18,589 | $3.20 | $59,414 | Direct |
| Sep 23, 2024 | AMLX Amylyx Pharmaceuticals, Inc. | Exercise(M) | 1,857 | $1.57 | $2,915 | Direct |
| Sep 12, 2024 | AMLX Amylyx Pharmaceuticals, Inc. | Exercise(M) | 34,449 | $1.57 | $54,085 | Direct |
1-21 of 21 transactions
About Cohen Joshua B
Cohen Joshua B (SEC CIK 0001898644) files insider reports with the SEC as Director of TCGX Acquisition Corp. II (TCXB) and Co-Chief Executive Officer of Amylyx Pharmaceuticals, Inc. (AMLX).
Signal8 holds 17 ownership filings by Cohen Joshua B (1 Form 3, 16 Form 4), filed between Sep 16, 2024 and Oct 20, 2026. Those filings report 21 transactions, from Sep 12, 2024 to Sep 10, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Cohen Joshua B's filings is in PALO ALTO, CA.
Recent filings by Cohen Joshua B
- Sep 10, 2026: Open-market sales of AMLX shares (2 lines, Form 4, code S).
- Aug 18, 2026: Grant or award of AMLX shares (Form 4, code A).
- Mar 5, 2026: Grant or award of AMLX shares (Form 4, code A).
- Mar 2, 2026: Open-market sale of AMLX shares (Form 4, code S).
- Feb 2, 2026: Open-market sale of AMLX shares (Form 4, code S).
Other insiders filing for TCGX Acquisition Corp. II (TCXB)
- Yu Chen-Ming, Chief Executive Officer
- HENDERSON MICHAEL THOMAS, Director
- McKenna Mark C., Director
- Skaling Craig David, Chief Financial Officer